Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progress toward a pathogen-free blood supply.

Jeffrey McCullough1

  • 1Department of Laboratory Medicine and Pathology and Biomedical Engineering Institute, University of Minnesota, Minneapolis, MN 55455, USA. mccul001@tc.umn.edu

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|June 28, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Model for Estimating the Burden of Disease of Transfusion-Transmitted Infection.

International journal of public health·2024
Same author

Results of clinical effectiveness of conventional versus Mirasol-treated Apheresis Platelets in Patients with Hypoproliferative Thrombocytopenia (MiPLATE) trial.

Transfusion·2024
Same author

SARS-CoV-2 seroprevalence among blood donors in Uganda: 2019-2022.

Transfusion·2023
Same author

The Mirasol Evaluation of Reduction in Infections Trial (MERIT): study protocol for a randomized controlled clinical trial.

Trials·2022
Same author

Impact of different pathogen reduction technologies on the biochemistry, function, and clinical effectiveness of platelet concentrates: An updated view during a pandemic.

Transfusion·2021
Same author

External Validation of a Widely Implemented Proprietary Sepsis Prediction Model in Hospitalized Patients.

JAMA internal medicine·2021
Same journal

Safety and Immunogenicity of the Live-Attenuated Quadrivalent Dengue Vaccine V181 Compared With Butantan-DV Among Healthy Adults in Brazil: A Randomized, Double-Blind, Phase 2 Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Low Post-Treatment Recurrence After a Shortened All-oral Regimen for Pulmonary Rifampicin- or Multidrug-Resistant Tuberculosis in Individuals without Prior Second-Line Drug Exposure in Kazakhstan.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Sepsis Diagnostic Excellence and its Association with Mortality in Adults with Potential Infection.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

10-Year Trends in Attributable and Contributable Mortality of Culture-Positive Invasive Aspergillosis in Patients with Hematologic Malignancies: Have We Reached the "Ceiling Efficacy Effect" of Modern Antifungals?

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Virologic Outcomes After LA ART Initiation with and without Viremia in Two Large U.S. Clinic Cohorts.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Andes Virus Exposure and Nosocomial Transmission Events to Healthcare Personnel: A Systematic Review.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
See all related articles

New pathogen inactivation methods aim to nearly eliminate transfusion-transmitted infections. These technologies treat donated blood, showing promise in clinical trials for platelets and red blood cells.

Area of Science:

  • Transfusion Medicine
  • Infectious Disease Control
  • Biotechnology

Background:

  • Current blood supply safety measures, including donor screening and laboratory testing, do not entirely eliminate the risk of transfusion-transmitted infections.
  • Existing strategies are insufficient to completely eradicate the threat of infectious agents in donated blood products.

Purpose of the Study:

  • To explore novel approaches for reducing transfusion-transmitted infections by treating donated blood to eliminate pathogen infectivity.
  • To evaluate the safety and efficacy of emerging pathogen inactivation technologies for blood products.

Main Methods:

  • Development of methods that prevent nucleic acid replication to inactivate contaminating viruses and bacteria in donated blood.
  • Assessment of toxicity, mutagenicity, safety margins, and impact on blood proteins and cellular components.

Related Experiment Videos

  • Clinical trials of pathogen-inactivated platelets and ongoing phase III trials for pathogen-inactivated red blood cells.

    • Main Results:

    • Pathogen inactivation methods demonstrate adequate safety margins with minimal damage to blood components.
    • Clinical trials for pathogen-inactivated platelets have concluded successfully in Europe and the US.
    • Phase III clinical trials for pathogen-inactivated red blood cells are progressing in the US.

    Conclusions:

    • Pathogen inactivation represents a promising strategy to significantly reduce, and potentially nearly eliminate, the risk of transfusion-transmitted diseases.
    • Continued research and clinical trials are essential to fully realize the potential of pathogen inactivation in ensuring blood product safety.